Suppr超能文献

人膀胱癌的免疫检测

Immunological detection of human bladder carcinoma.

作者信息

Monaco A P, Gozzo J J, Schlesinger R M, Codish S D

出版信息

Ann Surg. 1975 Sep;182(3):325-33. doi: 10.1097/00000658-197509000-00015.

Abstract

A rabbit antiserum (RABCa) to membrane antigenic extracts of human bladder carcinomas was produced. RABCa failed to detect bladder cancer-specific antigens in gel diffusion reaction against antigenic extracts of bladder carcinoma and normal bladder mucosa. However, RABCa showed higher complement fixation activity against urines from bladder cancer patients compared with normal urines. The micro-complement fixation (CF) assay (108 patients) was positive in 17 of 27 bladder cancer patients (62.9%) compared to only 1 of 29 normals (3.4%). However, 10 of 11 patients with urinary infections also were positive. A micro-Ouchterlony agar gel diffusion assay was also used to study urine samples (118 patients). RABCa produced separate precipitin bands against 20 of 30 bladder cancer urines (66.7%) while only 1 of 24 normal urines gave these bands (4.2%). Again, infected urines were positive (9 of 11). Additionally, urine from patients with benign urological disease was often positive in CF (11 of 41) and Ouchterlony (15 of 43) assays. RABCa serum was absorbed with normal bladder mucosa membrane extracts either once (1X) or three times (3X) to increase the specificity of the Ouchterlong gel diffusion assay. Using RABCa (1X) the per cent of positive bladder cancer urines and normals decreased only slightly, while the number of positive reactions against benign urological disease urines dramatically decreased (17.9%). RABCa (3X) further reduced the per cent of positive reactions with benign urological disease urines (10.3%), greatly reduced the reactivity with infected urines (60.0%), and gave no positive reactions with normal urines, without significantly decreasing the abiltiy to detect bladder carcinoma (51.9%). Although RABCa was 100% effective in detecting high grade (III) bladder tumors, almost two-thirds of all transitional cell papilloma urines were also positive. The nature of the material detected in bladder cancer and infected urines by RABCa is probably a product of in vivo inflammation. It does not appear to be part of the bacterial cell membrane or a bacterial metabolite. CEA (up to 10 ng/ml) did not produce positive precipitin bands with RABCa. Sephadex G-100 fractionation of urines suggests that RABCa reacts in the CF and Ouchterlony assays with a component or urine which has a molecular weight greater than 100,000-200,000 M.W. In summary, an antiserum has been prepared which may be used in micro-complement fixation and micro-Ouchterlony agar gel diffusion assays for immunological screening in the early detection of clinical disease, especially bladder cancer and urinary infection.

摘要

制备了一种针对人膀胱癌膜抗原提取物的兔抗血清(RABCa)。在针对膀胱癌和正常膀胱黏膜抗原提取物的凝胶扩散反应中,RABCa未能检测到膀胱癌特异性抗原。然而,与正常尿液相比,RABCa对膀胱癌患者尿液显示出更高的补体结合活性。微量补体结合(CF)试验(108例患者)中,27例膀胱癌患者中有17例呈阳性(62.9%),而29例正常患者中仅有1例呈阳性(3.4%)。然而,11例泌尿系统感染患者中有10例也呈阳性。还使用微量双向琼脂扩散试验研究尿液样本(118例患者)。RABCa对30例膀胱癌尿液中的20例产生了单独的沉淀带(66.7%),而24例正常尿液中只有1例出现这些带(4.2%)。同样,感染尿液呈阳性(11例中有9例)。此外,良性泌尿系统疾病患者的尿液在CF试验(41例中有11例)和双向琼脂扩散试验(43例中有15例)中常常呈阳性。用正常膀胱黏膜膜提取物对RABCa血清进行一次(1X)或三次(3X)吸收,以提高双向琼脂扩散试验的特异性。使用RABCa(1X)时,膀胱癌阳性尿液和正常尿液的百分比仅略有下降,而针对良性泌尿系统疾病尿液的阳性反应数量显著减少(17.9%)。RABCa(3X)进一步降低了良性泌尿系统疾病尿液的阳性反应百分比(10.3%),大大降低了与感染尿液的反应性(60.0%),且对正常尿液无阳性反应,同时又不显著降低检测膀胱癌的能力(51.9%)。尽管RABCa在检测高级别(III级)膀胱肿瘤方面100%有效,但几乎三分之二的所有移行细胞乳头状瘤尿液也呈阳性。RABCa在膀胱癌和感染尿液中检测到的物质的性质可能是体内炎症的产物。它似乎不是细菌细胞膜的一部分或细菌代谢产物。癌胚抗原(高达10 ng/ml)与RABCa未产生阳性沉淀带。尿液的葡聚糖G - 100分级分离表明,RABCa在CF试验和双向琼脂扩散试验中与分子量大于100,000 - 200,000 M.W. 的尿液成分发生反应。总之,已制备出一种抗血清,可用于微量补体结合试验和微量双向琼脂扩散试验,用于临床疾病尤其是膀胱癌和泌尿系统感染早期检测的免疫筛查。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7e4/1343948/66f48a5b282c/annsurg00283-0167-a.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验